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OBJECTIVES The purpose of this study was to elucidate whether the neuronal noradrenaline reuptake
transporter (uptake1) undergoes age-dependent regulation in the human heart.
BACKGROUND Aging is associated with various alterations in cardiovascular function.
METHODS We determined uptake1 density (by [
3H]-nisoxetine binding to membranes) and activity (by
accumulation of [3H]-noradrenaline into tissue slices) in the right atria (RA) of 42 patients
(age range 3 months to 76 years) undergoing open-heart surgery without apparent heart
failure. Moreover, the effects of 1 mol/l desipramine on the noradrenaline-induced positive
inotropic effect were assessed in the isolated, electrically driven RA trabeculae of these
patients.
RESULTS There was a significant negative correlation between RA uptake1 density and age; moreover,
RA uptake1 activity was significantly reduced in elderly patients. Desipramine (1 mol/l)
significantly shifted noradrenaline concentration-response curves to the left; this shift was
significantly more pronounced in younger patients than in older patients.
CONCLUSIONS With increasing age, human myocardial uptake1 activity decreases, possibly because of
age-dependent downregulation of uptake1 density. (J Am Coll Cardiol 2002;40:1459–65)
© 2002 by the American College of Cardiology Foundation
Aging is associated with reduced responsiveness of many
hormone receptors. Numerous studies in animal models of
aging, but also in humans, have shown that cardiac beta-
adrenoceptor function declines with aging (1–3). The
mechanism underlying this age-dependent reduction in
cardiac beta-adrenoceptor function is not completely under-
stood. It has repeatedly been shown that plasma noradren-
aline levels are higher in elderly than in young people (4–6).
Measurements of plasma noradrenaline levels are generally
taken as an index of sympathetic activity (7); thus, increases
in plasma noradrenaline might reflect increases in sympa-
thetic activity with aging. Such an increased sympathetic
activity, which has been directly demonstrated by microneu-
rographic recordings from the sympathetic nerves of elderly
subjects (8,9), could likely cause prolonged stimulation of
cardiac beta-adrenoceptors, which finally leads to desensi-
tization of cardiac beta-adrenoceptor function often ob-
served in the elderly.
However, in the synaptic cleft, action of noradrenaline at
the receptors is terminated by reuptake into sympathetic
nerve terminals through the neuronal uptake1 transporter
(10,11). Thus, an age-dependent reduction in activity of this
transporter would also lead to prolonged action of noradren-
aline at beta-adrenoceptors and could thus contribute to
cardiac beta-adrenoceptor desensitization with aging. In
fact, there is indirect evidence that, with aging, neuronal
uptake of noradrenaline declines (6,12). However, direct
measurements of neuronal uptake1 sites and neuronal up-
take1 activity in aging human hearts are missing.
We have recently shown that, in rat cardiac membranes,
(3H)-nisoxetine binding and, in rat cardiac tissue slices,
assessment of (3H)-noradrenaline accumulation can be used
to identify sites that have characteristics of the cardiac
neuronal uptake1 transporter (13).
In this study, we used these techniques to assess the
density and activity of the neuronal uptake1 transporter in
the right atria (RA) obtained from 42 patients (age range 3
months to 76 years) during open-heart surgery without
apparent heart failure. Moreover, to get further insight into
the functional consequences of possible changes in uptake1
activity, we assessed, in the isolated, electrically driven RA
trabeculae of these patients, the effects of the uptake1
blocker desipramine on positive inotropic effects evoked by
noradrenaline through beta-adrenoceptor stimulation.
METHODS
Patients. Right atrial appendages were obtained from: 1)
19 patients (9 male and 10 female; age range 3 months to 21
years) with acyanotic congenital heart disease who under-
went open-heart surgery because of a ventricular septal
defect (n  8) or atrial septal defect (n  11). Their parents
had given informed, written consent. The study was ap-
proved by the local Ethics Committee. None of the children
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or young adults had acute heart failure or had been treated
with sympathomimetic or sympatholytic agents for at least
three weeks before the operation. Anesthesiologic premed-
ication and surgery were carried out exactly as recently
described (14,15). Right atrial appendages were removed
immediately after installation of the cardiopulmonary by-
pass. 2) Twenty-three adult patients with coronary artery
disease (18 male and 5 female; age range 45 to 76 years)
undergoing coronary artery bypass graft surgery without
apparent heart failure (New York Heart Association
[NYHA] functional class 0/I: n  5; class II: n  18) after
having given informed, written consent. The study was
approved by the local Ethics Committee. None of these
patients had been treated with sympathomimetic or sympa-
tholytic drugs for at least six weeks before the operation.
However, patients had received nitrates (n  9), calcium
antagonists (n  3), diuretics (n  6), hydroxymethyl
glutaryl coenzyme A reductase inhibitors (n  16), acetyl
salicylic acid (n  7), and, occasionally, digitalis glycosides
(n  2), alone or in combination. Anesthesiologic premed-
ication and surgery were carried out exactly as recently
described (14,15). In all patients, RA appendages were
removed during installation of cardiopulmonary bypass.
Immediately after excision, the specimens were either
quickly frozen in liquid nitrogen and stored at 80°C (for
[3H]-nisoxetine binding) or transferred into carbogenated
(95% O2/5% CO2) Tyrode’s solution (mmol/l: NaCl 119.8,
KCl 5.4, CaCl2 1.8, MgSO4 1.05, NaH2PO4 0.42,
NaHCO3 23.6, glucose 5.05, EDTA 0.05, and ascorbic acid
0.28; at room temperature) and transported to the labora-
tories. Experiments for positive inotropic effects in RA
trabeculae were started usually within 15 to 30 min after
excision; experiments for (3H)-noradrenaline accumulation
into RA tissue slices were started within 1 to 2 h after
excision. Patients were classified into two age groups: group
A included children (mean age 12  3 years; range 3
months to 21 years); group B included elderly patients
(mean age 60  3 years; range 45 to 76 years). The clinical
characteristics of the patients are given in Table 1.
Contraction studies. Preparation of tissues was performed
in oxygenated Tyrode’s solution (see previous description) at
room temperature to minimize inadequate oxygenation.
Right atrial appendages were dissected to yield trabecular
strips (4–5 mm in length and 1 mm in diameter) without
endocardial damage and with fibers running parallel to the
length. Preparations were used only if at least two function-
ing trabecular strips were obtained. Preparations were
mounted in a 10-ml organ bath containing carbogenated
Tyrode’s solution at 37°C. Atrial strips were electrically
stimulated by rectangular pulses (5 ms) 20% above the
threshold (mean 8 V; range 3–12) at a frequency of
stimulation of 1.0 Hz (Stimulator II, Hugo Sachs Elek-
tronik KG, March-Hugstetten, Germany). The developed
tension of the preparation (maintained under a rest tension
of 4.9 mN) was recorded via a strain gauge on a Hellige
recorder (Hellige GmbH, Freiburg, Germany). Prepara-
tions were allowed to equilibrate for at least 1 h in Tyrode’s
solution; phentolamine (1 mol/l) was present throughout
the experiments to block alpha-adrenoceptors.
Thereafter, preparations were incubated with 1 mol/l
desipramine or vehicle for 30 min, followed by cumulative
concentration-response curves for noradrenaline (108 to
104 mol/l) constructed as detailed elsewhere (16). Each
muscle preparation was used for one concentration-response
curve only to exclude desensitization phenomena.
(3H)-nisoxetine binding. To determine neuronal nor-
adrenaline transporter (NAT) density, crude membranes
were isolated as recently described (13), with minor modi-
fications. Briefly, frozen tissue was thawed on ice in ice-cold
incubation buffer (mmol/l: Na2HPO4 10, NaCl 120, KCl 5;
pH 7.4) containing 0.25 mol/l sucrose. Fatty and connective
tissues were carefully removed, and 100 to 150 mg of the
remaining tissue was minced with scissors and gradually
homogenized with an Ultra-Turrax (Ultra-Turrax T25,
Janke & Kunkel IKA Labortechnik, Germany) at 24,000
rpm for 10 s and twice at 17,500 rpm for 20 s with 1-min
intervals on ice. The homogenate, brought up to 10 ml with
incubation buffer (with 0.25 mol/l sucrose), was centrifuged
for 10 min at 1,200 g at 4°C. The supernatant was filtered
through four layers of cheesecloth and centrifuged for 20
min at 20,000 g at 4°C. The resulting pellet was resus-
pended in 10 ml of incubation solution (without sucrose),
and the protein content was determined according to
Bradford (17), using bovine gamma-globulin as a standard.
Saturation analysis of (3H)-nisoxetine was performed by
incubating 100 g protein/assay with six concentrations of
(3H)-nisoxetine, ranging from 0.3125 to 10 nmol/l in a final
volume of 500 l for 3 h at 4°C. Nonspecific binding of
(3H)-nisoxetine was defined as binding in the presence of 1
mol/l desipramine. Specific binding was defined as total
binding minus nonspecific binding and amounted to 80%
at 2 nmol/l (3H)-nisoxetine. All incubations were per-
formed in duplicate.
To assess the ability of the noradrenaline uptake inhibi-
tors desipramine, nisoxetine, and cocaine and the dopamine
Abbreviations and Acronyms
RA  right atrium/atria/atrial
NAT  neuronal noradrenaline transporter
NYHA  New York Heart Association
Table 1. Clinical Characteristics of the Patients
Group A
(n  19)
Group B
(n  23)
Age (yrs) 12  3 60  3
Gender (M/F) 9/10 18/5
LVEF (%) 71  3 (3) 62  5 (12)
HR (beats/min) 86  7 (8) 71  6 (16)
Data are presented as the mean value  SEM or number of patients (in parentheses).
HR  heart rate; LVEF  left ventricular ejection fraction.
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transporter antagonist GBR 12909 to inhibit specific (3H)-
nisoxetine binding, membranes (100 g protein/assay) were
incubated with 2 nmol/l (3H)-nisoxetine in the presence of
10 different concentrations of the competing agent for 3 h at
4°C, and specific binding was determined as described
earlier.
(3H)-noradrenaline uptake1 activity. Activity of NAT
was assessed as recently described (13), with minor modi-
fications. Briefly, RA appendages transported in Tyrode’s
solution were allowed to equilibrate in modified and carbo-
genated Krebs-Henseleit solution (mmol/l: NaCl 118, KCl
4.7, CaCl2 2.5, MgCl2 0.54, NaHCO3 25, NaH2PO4 1,
glucose 11, EDTA 0.094, ascorbic acid 1.14, nialamide
0.067) for at least 30 min at room temperature. After
equilibration, fatty and connective tissues were carefully
removed, and the remaining RA appendage tissue was
chopped into 250  250 m slices with a McIllwain tissue
chopper (Bachhofer, Reutlingen, Germany). Slices were
resuspended in fresh Krebs-Henseleit solution and allowed
to equilibrate for further 15 min at 37°C. Activity of NAT
was measured by incubating 10 mg tissue slices/assay at
37°C for 15 min in carbogenated Krebs-Henseleit solution
containing 1.56, 3.125, 6.25, 12.5, and 25 nmol/l D,L-(7-
3H[N])-noradrenaline hydrochloride in the presence of 40
mol/l corticosterone (specific uptake2 blocker) in a final
volume of 500 l. Nonspecific accumulation of radioactivity
was determined by parallel incubation at 4°C. Specific
uptake was defined as total uptake (37°C) minus nonspecific
uptake (4°C). All incubations were performed in duplicate.
Statistics. Experimental data given in the text, figures, and
table are expressed as the mean value SEM of the number
of experiments. The equilibrium dissociation constant (KD)
and the maximal number of binding sites (Bmax) for (
3H)-
nisoxetine binding were calculated by nonlinear regression
analysis (hyperbolic function: y  Bmax  x/[KD  x]),
using the iterative curve-fitting Prism program (Graph-Pad
Software, San Diego, California). One-site competition
curves (y bottom [top bottom]/[1 10(x  log EC50)],
with x  log [antagonist concentration] and y  [3H]-
nisoxetine binding) were analyzed using the iterative curve-
fitting program Prism from which the individual IC50 values
(concentration of competitor to inhibit specific [3H]-
nisoxetine binding by 50%) were obtained. Experimental
data of contraction studies were fitted and analyzed by
computer-supported iterative nonlinear regression analysis
(sigmoidal concentration-response curve: y  bottom 
[top bottom]/[1 10(log EC50  x)], with x logarithm of
agonist concentration and y  response), using the Prism
program. Linear regression analysis of data was performed
by the least-squares method (model: [3H]-nisoxetine bind-
ing sites a age b). The significance of differences was
estimated by using the nonpaired two-tailed Student t test
or, to evaluate possible gender differences, by repeated
measures analysis of variance followed by the t test with the
Bonferroni correction for multiple comparisons (age, Bmax,
and gender: n  18). All statistical calculations were
performed using the Prism program. A p value 0.05 was
considered significant.
Drugs used. D,L-(7-3H[N])-noradrenaline hydrochloride
(specific activity: 13.5 Ci/mmol) and (N-methyl-3H)-
nisoxetine (specific activity: 80 Ci/mmol) were purchased
from NEN Life Science Products, Inc. (Boston, Massachu-
setts); desipramine hydrochloride from RBI (Natick, Mas-
sachusetts); and corticosterone, (-)-noradrenaline bitartrate,
and nialamide from Sigma (Deisenhofen, Germany). All
other chemicals were of the purest grade commercially
available.
RESULTS
(3H)-nisoxetine binding. (3H)-nisoxetine binding
(0.3125–10 nmol/l) to RA membranes was saturable and
had a high affinity (KD values1 nmol/l) (Fig. 1A). Uptake
inhibitors inhibited (3H)-nisoxetine binding with the fol-
lowing order of potency: desipramine  nisoxetine 
cocaine  GBR 12909 (Fig. 1B), which is typical of
noradrenaline uptake1 (13).
However, the maximal number of binding sites in group
A (7 children [5 males and 2 females]; mean age 14  3
years [range 4 to 21]) was significantly higher (163  4.5
fmol/mg protein) than that in group B (11 elderly patients
[8 males and 3 females]; mean age 60  3 years [range 45
to 76]) (105  8.2 fmol/mg protein; p  0.001) (Fig. 1A).
Moreover, for all 18 patients, the RA NAT density was
significantly negatively correlated with age (p  0.0001)
(Fig. 2). The KD values for (
3H)-nisoxetine, however, were
not significantly different between group A (1,091  101
pmol/l) and group B (724  214 pmol/l). Repeated mea-
sures analysis of variance of these data revealed no statisti-
cally significant influence of gender.
(3H)-noradrenaline uptake. Next, we determined NAT
activity by assessment of (3H)-noradrenaline (1.56–25
nmol/l) (see Methods) accumulation in RA slices. As shown
in Figure 3, (3H)-noradrenaline accumulation in RA slices
was directly related to the (3H)-noradrenaline concentration
present in the media. Moreover, at each (3H)-noradrenaline
concentration, the NAT activity was significantly higher in
group A (children) than in group B (elderly patients) (Fig.
3). However, because of a limited amount of tissue, we
could only determine the (3H)-noradrenaline accumulation
at all five (3H)-noradrenaline concentrations in four of the
seven children, whereas in the remaining three children, the
(3H)-noradrenaline accumulation was determined only at
the 25 nmol/l (3H)-noradrenaline concentration. Thus, in
addition, we calculated the data obtained at 25 nmol/l
(3H)-noradrenaline in all seven children (group A) and in
five elderly patients (group B). This analysis revealed that
NAT activity was significantly higher (208  13 pmol
noradrenaline/mg tissue per 15 min) in seven children of
group A (mean age 4 3 years [range 3 months to 6 years];
n  7) than in five elderly patients of group B (mean age 59
1461JACC Vol. 40, No. 8, 2002 Leineweber et al.
October 16, 2002:1459–65 Age Dependence of Human Myocardial Uptake1
 5 years [range 48 to 62]) (118  5.1 pmol noradrena-
line/mg tissue per 15 min; p  0.001).
Positive inotropic effects of noradrenaline. Thus, in the
human RA, NAT density and activity decrease with in-
creasing age. To study the functional consequences of these
changes in a final set of experiments, we assessed the
influence of uptake1 inhibition by desipramine on the
positive inotropic effects of noradrenaline mediated by
beta-adrenoceptors in isolated, electrically driven RA prep-
arations obtained from five children of group A (3 males and
2 females; mean age 9  4 years [range 5 to 12]) and seven
elderly patients of group B (5 males and 2 females; mean age
60  3 [range 56 to 63]).
In both groups, the noradrenaline concentration depen-
dently increased the force of contraction (Fig. 4). The
potency of noradrenaline (pD2 value  negative logarithm
of the molar concentration of noradrenaline causing half-
maximal effects) was 5.8  0.03 in group A and 6.0  0.06
in group B. Desipramine at 1 mol/l increased the basal
force of contraction (see legend to Fig. 4) and shifted the
concentration-response curves of noradrenaline to the left
(Fig. 4). However, this shift was significantly larger in
children (	pD2 value: 1.2  0.05) than in elderly patients
(	pD2 value: 0.8  0.06; p  0.001).
DISCUSSION
With aging, plasma noradrenaline increases 10% to 15% per
decade due to enhanced spillover of noradrenaline into the
circulation (12,18). Such increased plasma noradrenaline
levels could be the result of increased sympathetic activity or
decreased plasma clearance of noradrenaline through up-
take1 (12,19). Increased sympathetic activity with aging has
been demonstrated by direct microneurographic recordings
from sympathetic nerves to skeletal muscle (8,9). However,
indirect evidence from noradrenaline-spillover studies indi-
cate that an age-dependent reduction in NAT activity
might contribute to the increase in plasma noradrenaline
with aging (1,12,20).
Uptake1 is reduced in the aging human heart. We have
recently shown that, in rat ventricular crude membranes,
(3H)-nisoxetine binding was inhibited by uptake1 inhibitors
with the following order of potency: desipramine  nisox-
etine  cocaine  GBR 12909 (13). In this study, uptake1
inhibitors inhibited (3H)-nisoxetine binding to human RA
membranes with the same order of potency (Fig. 1B).
Moreover, the same order of potency was also found for
inhibition of (3H)-noradrenaline accumulation (measure of
NAT activity) in rat ventricular slices (13). Thus, assess-
ment of (3H)-noradrenaline accumulation in cardiac slices
Figure 1. (A) Concentration-dependent binding of (3H)-nisoxetine to
membranes obtained from the right atria (RA) of 5 children and 2 young
adults in group A (5 males and 2 females; mean age 14  3 years) and 11
elderly patients in group B (8 males and 3 females; mean age 60  3 years)
(New York Heart Association functional class 1.73  0.19). Ordinate:
(3H)-nisoxetine concentration in fmol specifically bound/mg protein;
abscissa: (3H)-nisoxetine concentration in nmol/l. Data are presented as
the mean value  SEM. ***p  0.001 vs. group A. (B) Inhibition of
specific (3H)-nisoxetine binding (2 nmol/l) to RA membranes obtained
from 8 elderly patients (6 males and 2 females; mean age 67  3 years) by
uptake inhibitors. Ordinate: specific (3H)-nisoxetine binding as percent;
abscissa: molar concentrations of uptake inhibitors. Data are presented as
the mean value SEM of two experiments performed in triplicate with log
(mol/l) IC50 values: desipramine 7.51  0.20; nisoxetine 7.09  0.06;
cocaine 5.52  0.08; and GBR 12909 5.35  0.10.
Figure 2. Correlation (solid line  linear regression) between right atrial
(RA) neuronal noradrenaline transporter (NAT) density and age of 18
patients (see Fig. 1A). Ordinate: RA NAT density in fmol of (3H)-
nisoxetine specifically bound/mg protein; abscissa: age of patients in years.
Solid line: y  1.104x  177.4; r  0.906; R2  0.644; p  0.0001.
Dotted lines represent 95% confidence limits for the regression line.
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and (3H)-nisoxetine binding to cardiac membranes can be
used to determine cardiac NAT activity and density.
In the present study, we determined, by these techniques
directly, human cardiac NAT density and activity in RA
appendages from patients with a wide range of age. We
found that NAT density was significantly lower in elderly
patients (mean age 60 3 years) than in children (mean age
14 3 years). This age-dependent decrease in NAT density
was accompanied by a similar loss in NAT activity; in
elderly patients, NAT activity was 50% lower than that in
children. Such an age-dependent loss in NAT activity could
explain why the myocardial noradrenaline content is re-
duced in aging hearts (21,22).
The mechanism underlying decreases in cardiac NAT
density and activity with aging is not known at present;
however, it should be considered that in the human myo-
cardium, there is a progressive age-dependent loss of myo-
cytes (23) and sympathetic nerves (24), which might likely
contribute to a reduction in transporter density with aging.
Beta-adrenoceptors are desensitized in the aging human
heart. It is well known that with aging, cardiac beta-
adrenoceptor function declines (1,2,3,25). We have previ-
ously shown that in the RA of patients of different ages (7
days to 83 years), beta-adrenoceptor–mediated adenylyl
cyclase activation significantly decreased with age; beta-
adrenoceptor density, however, was only marginally altered.
Moreover, in these RA, the potency of isoprenaline to
increase the force of contraction significantly decreased with
age (14). Similarly, decreased beta-adrenoceptor–mediated
adenylyl cyclase activation and inotropic potency of isopren-
aline were also found in ventricular preparations of aging
human hearts (26–28). However, this was accompanied by
decreased beta-adrenoceptor density (27). Thus, human
cardiac beta-adrenoceptors are also desensitized with in-
creasing age (3,25).
Functional consequence of reduced uptake1 in the aging
human heart. In the present study, however, the potency of
noradrenaline to induce positive inotropic effects in isolated
RA was very similar in young and elderly patients. However,
isoprenaline is not a substrate for NAT (29,30), although
noradrenaline is. Therefore, it is very likely that, due to
reduced NAT activity (as seen in the present study),
noradrenaline is not as sufficiently inactivated in elderly
patients as in young patients. This results in higher nor-
adrenaline concentrations at beta-adrenoceptors, thus
masking the reduced beta-adrenoceptor responsiveness usu-
ally seen in elderly patients. If this hypothesis holds true,
one should expect that in the presence of uptake1 blockers,
concentration-response curves for positive inotropic effects
of noradrenaline should be shifted to the left and more
Figure 3. Specific (3H)-noradrenaline uptake1 in right atrial (RA) slices obtained from 4 children of group A (A) (2 males and 2 females; mean age 5 
2 years) and 5 elderly patients of group B (B) (5 males; mean age 59  5 years) (New York Heart Association functional class 1.80  0.20). Ordinate:
specific (3H)-noradrenaline uptake1 (in the presence of 40 mol/l corticosterone) in pmol (
3H)-noradrenaline/mg tissue per 15 min; abscissa:
(3H)-noradrenaline concentrations in nmol/l. Data are presented as the mean value  SEM. **p  0.01 and ***p  0.001 vs. group A.
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pronounced in young than in elderly patients. This was,
indeed, the case (Fig. 4): in the RA from young patients,
desipramine shifted the noradrenaline concentration-
response curve to the left by 1.2 log units, whereas in elderly
patients, this shift was only 0.8 log units (Fig. 4).
The present result of reduced NAT activity in elderly
patients might also explain the differences in the effects of
age on heart rate responses to isoprenaline and adrenaline
infusion, as recently described by White and Leenen
(31,32): heart rate increases were nearly identical in young
(age 30 years) and elderly volunteers (age 60 years); gangli-
onic blockade with trimethaphan unmasked decreased chro-
notropic responses to isoprenaline in elderly patients, but
did not affect adrenaline-induced heart rate increases. As
mentioned earlier, isoprenaline is not a substrate for up-
take1, although adrenaline is. Thus, it is very likely that, due
to reduced NAT activity, during adrenaline infusion, adren-
aline concentrations at beta-adrenoceptors are higher in
elderly volunteers than in young volunteers, thereby com-
pensating for the age-dependent decrease in chronotropic
response to beta-adrenoceptor stimulation.
Study limitations. In this study, we observed age-
dependent differences in children verses elderly patients.
Children were quite young (mean age 12 years), and elderly
patients were not completely healthy but had a mild cardiac
diagnosis. Thus, the changes observed in this study may not
be entirely due to aging but may have occurred during
maturation or may be, at least partly, due to the beginning
of mild heart failure (in all subsets of patients studied,
NYHA functional class was II). We cannot exclude these
possibilities, and it will be rather impossible to obtain tissue
samples from normal human hearts from patients with a
more appropriate age distribution. However, we recently
found in patients with a similar age distribution, significant
correlations between age and RA adenylyl cyclase activation
(14), as well as age and RA muscarinic receptors (15). Thus,
we are quite sure that, in this study, changes in RA uptake1
activity are predominately due to aging.
Conclusions. The density of the RA NAT is decreased in
patients 60 years old, as compared with young patients, and
this is accompanied by decreased NAT activity. The patho-
physiologic consequence of such decreased NAT activity
could be increased noradrenaline concentrations in the
synaptic cleft at beta-adrenoceptors, and this might contrib-
ute to desensitization of cardiac beta-adrenoceptors often
observed in aging.
Finally, the present results add further to the growing list
of similarities between aging and failing human hearts: in
both settings, plasma catecholamines are increased; the
myocardial catecholamine content is decreased; and the
responses to stimulation of all receptors that involve intra-
cellular cyclic adenosine monophosphate increases are di-
minished (3,25,33). In addition, not only in failing human
hearts (34,35), but also in aging human hearts (as in the
present study), NAT density and activity are diminished.
Figure 4. Effects of 1 mol/l desipramine (DMI) on the positive inotropic effect of noradrenaline (in the presence of 1 mol/l phentolamine) in right atrial
(RA) trabecular strips obtained from 5 children in group A (A, left panel) (3 males and 2 females; mean age 9  4 years) and from 7 elderly patients in
group B (B, right panel) (5 males and 2 females; mean age 60  3 years) (New York Heart Association functional class 1.71  0.18). Ordinates: positive
inotropic effect in percent maximal response; abscissa: molar concentrations of noradrenaline. The basal force of contraction was 2.5  0.4 mN (without
DMI) and 5.0  0.8 mN (with DMI) in group A and 3.6  0.6 mN (without DMI) and 4.2  1.3 mN (with DMI) in group B. The maximal force of
contraction was 7.2  0.6 mN (without DMI) and 6.7  1.0 mN (with DMI) in group A and 8.7  0.7 mN (without DMI) and 6.1  1.3 mN (with
DMI) in group B. Data are presented as the mean value  SEM.
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